Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5611082 | 1.00 | NPC1 (0.42) | NPC1NPSR1MAPTALDH1A1CA9 | |
| SCHEMBL14586877 | 1.00 | NPC1 (0.42) | NPC1NPSR1MAPTALDH1A1CA9 | |
| SCHEMBL5611040 | 0.79 | MAPT (0.34) | MAPTALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL14586878 | 0.79 | MAPT (0.34) | MAPTALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL5611038 | 0.79 | MAPT (0.34) | MAPTALDH1A1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL5611076 | 0.77 | MAPT (0.40) | MAPTALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5611077 | 0.77 | MAPT (0.40) | MAPTALDH1A1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL5611072 | 0.69 | GFER (0.47) | NPC1MAPTALDH1A1CA9MAPK1 | |
| SCHEMBL14586907 | 0.69 | GFER (0.47) | NPC1MAPTALDH1A1CA9MAPK1 | |
| SCHEMBL5611068 | 0.69 | GFER (0.47) | NPC1MAPTALDH1A1CA9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183302-B2 | Iminothiazolidinones as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20050096364-A1 | Iminothiazolidinones as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
| US-20050069522-A1 | Combination pharmaceutical agents as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | disclosed |
| WO-2004014313-A2 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014852-A2 | IMINOTHIAZOLIDINONES AS INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050069522-A1 | Combination pharmaceutical agents as inhibitors of HCV replication | IMPDH1, IMPDH2, IMPA1 | NPC1 325/4885NPSR1 3142/4885MAPT 4776/4885 |
| US-20050096364-A1 | Iminothiazolidinones as inhibitors of HCV replication | EIF2AK2, RTF2, IFNAR1 | NPC1 2383/4885NPSR1 3739/4885MAPT 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.